[Virus inactivated plasma]

Area of Science:

• Blood product safety and efficacy
• Viral inactivation technologies
• Plasma derivative analysis

Background:

• Germany offers two primary virus-inactivated plasma preparations: Methylene Blue (MB) and Solvent Detergent (SD) plasma.
• Both methods aim to mitigate viral transmission risks in transfusion medicine.

Purpose of the Study:

• To compare the characteristics and clinical implications of MB and SD plasma.
• To evaluate the efficacy and safety profiles of these two plasma products.

Main Methods:

• MB plasma undergoes photoxidation with methylene blue and visible light.
• SD plasma is treated with Triton X-100 and tri-n-butyl phosphate after pooling donations.
• Analysis of viral reduction, protein alterations (fibrinogen, protein S, alpha-2-antiplasmin), and clinical efficacy.

Main Results:

• MB plasma photoxidation inactivates HIV by over 5 log10 but alters fibrinogen, with unclear clinical significance.
• SD plasma treatment reduces HIV and hepatitis viruses by 5–6 log10 and decreases protein S and alpha-2-antiplasmin by approximately 40%.
• Clinical studies indicate SD plasma's efficacy is comparable to untreated fresh frozen plasma.

Conclusions:

• SD plasma demonstrates established efficacy and safety, comparable to fresh frozen plasma.
• Further clinical studies are needed to ascertain the clinical significance of fibrinogen alterations in MB plasma.
• Both MB and SD plasma represent advancements in ensuring safer blood transfusions.